slides · global inventory
Problem Agitate Solution
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 26,550
Current window 20,671-20,700
Pages 885
Rows per page 30
Arc
20,671-20,700 of 26,550
04
The slide displays two forest plots showing confidence intervals for vaccine effectiveness across multiple studies.Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
The slide presents experimental data from a study on live-attenuated pneumococcal vaccines.Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
08
The slide presents preclinical data comparing a vaccine candidate (BHN97ΔftsY) against a control (Mock) and a standard (PCV13).Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
09
The slide presents three sets of survival plots (Kaplan-Meier style) and corresponding bacterial load scatter plots for three different serotype challenges.Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
10
The slide uses bioluminescence imaging to visualize bacterial load in the ear region of mice.Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
11
Data presented as scatter plots with horizontal bars indicating means; statistical significance markers included.Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
12
The diagram uses question marks to represent the unknown or challenging nature of integrating different protein types into the central platform.Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
13
The data shows ELISA absorbance results comparing vehicle (PBS) to the vaccine construct (LAV-D-M1) across four different pathogen serotypes/species.Blue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
14
Blue Water Vaccines | Results Presentation Deck | 15 slidesBlue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · SolutionLoop · Jobs To Be Done1 hit
15
Blue Water Vaccines | Results Presentation Deck | 15 slidesBlue Water Vaccines | Results Presentation Deck | 15 slides · Blue Water Vaccines
Conference presentation Investor relations Beat · Action1 hit
01
BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slidesBrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · Problem1 hit
02
The chart is a dot plot comparing baseline ALSFRS-R scores across various clinical trials, highlighting NurOwn's lower baseline.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
03
The slide highlights a subgroup analysis where the treatment effect becomes statistically significant (p=0.050) in the secondary endpoint.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · ProblemLoop · Before After1 hit
04
BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slidesBrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
05
The slide uses a timeline-based process diagram to explain the clinical trial structure.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · AgitateLoop · Before After1 hit
06
Mentions specific statistical models: PCA, MMRM, and mixed stepwise regression.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
07
The slide outlines the primary endpoint (Clinical Response) and a secondary/supporting metric (piecewise slope) for ALS clinical trials.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
08
The slide details the specific biomarkers used in the study and the exclusion criteria based on missing data.BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · SolutionLoop · Before After1 hit
14
BrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slidesBrainStorm Cell Therapeutics | Investor Presentation Deck | 15 slides · Brainstorm Cell Therapeutics
Conference presentation Investor relations Beat · Solution1 hit
01
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
02
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
03
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
04
Note the typo in 'OPPENING' on the slide.Braskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
05
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Setup1 hit
06
Braskem | ESG Presentation Deck | 54 slidesBraskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
07
The slide uses a dual-row timeline structure to highlight key events in corporate sustainability.Braskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
08
The slide uses a split-layout to contrast internal goal achievement with external validation.Braskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
09
The slide uses a central hub-and-spoke style diagram to connect pillars to ambitions, with a footer emphasizing safety as a non-negotiable value.Braskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
10
The slide uses a three-column layout to define strategic pillars.Braskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · ComplicationLoop · Cost Of Inaction1 hit
11
The slide uses a dual-pillar structure to present sustainability goals and quantitative targets for 2025, 2030, and 2050.Braskem | ESG Presentation Deck | 54 slides · Braskem
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit